Azithromycin is Compatible with Breastfeeding
Azithromycin can be safely used during breastfeeding, as it is excreted into breast milk in very low concentrations that pose minimal risk to the infant. The most recent and comprehensive guidelines consistently support its use in lactating mothers 1.
Evidence Supporting Safety
The 2025 UK Guidelines for eosinophilia management explicitly state that azithromycin achieves "very low levels" in breast milk and is "likely to be compatible with breastfeeding" 1. The 2020 ERS/TSANZ Task Force on airways diseases classifies azithromycin as "probably safe" during breastfeeding 2.
The FDA drug label acknowledges that "it is not known whether azithromycin is excreted in human milk" but recommends caution should be exercised 3. However, this conservative FDA language predates more recent pharmacokinetic studies.
Pharmacokinetic Data
Research demonstrates that azithromycin concentrations in breast milk are sustained but remain at levels that result in minimal infant exposure 4. A 2015 study measuring azithromycin in breast milk of African mothers found the median cumulative infant dose was 15.7% of the maternal dose, with an absolute dose of 4.5 mg/kg 5. While this exceeded the theoretical 10% safety threshold, the clinical significance remains uncertain.
Important Caveat: Infantile Hypertrophic Pyloric Stenosis (IHPS)
The primary concern is a very low risk of infantile hypertrophic pyloric stenosis (IHPS) when macrolides are used during the first 13 days of breastfeeding. Multiple guidelines cite epidemiological data suggesting this association 2. The 2005 CDC pertussis guidelines note that erythromycin carries IHPS risk in neonates, and while azithromycin is preferred, infants receiving macrolides should be monitored 6.
However, this risk appears confined to:
- The first 2 weeks of life only (not after 2 weeks) 2
- Primarily associated with erythromycin rather than azithromycin 6
- Represents a very low absolute risk 2
The worst-case number needed to harm for IHPS has been estimated at 60 based on available data 5.
Clinical Recommendations
For infants >2 weeks old: Azithromycin is compatible with breastfeeding without special precautions.
For neonates <2 weeks old:
- Azithromycin remains the preferred macrolide if treatment is necessary 6
- Monitor the infant for signs of IHPS (projectile vomiting, visible peristaltic waves, palpable "olive" mass)
- The benefit of treating maternal infection typically outweighs the very low IHPS risk
Additional monitoring considerations:
- Watch for gastrointestinal effects in the infant (vomiting, diarrhea, candidiasis) due to alteration of intestinal flora 7
- Most systemic antibiotics in breast milk could theoretically cause falsely negative cultures in febrile infants 2
Context from Other Conditions
The 2025 CDC tularemia guidelines note that azithromycin concentrations in breast milk are typically low, and breastfeeding infants should be monitored for vomiting, diarrhea, and candidiasis 7. The medication has been used safely in mass drug administration programs, with calls to include pregnant and breastfeeding women in trachoma eradication efforts 8.
Bottom line: Continue breastfeeding while taking azithromycin. The only heightened vigilance needed is monitoring for IHPS symptoms during the first 2 weeks of the infant's life.